Physicians and their patients with acromegaly will soon have access to the first drug specifically designed to block the effects of human growth hormone. The FDA recently approved pegvisomant (Somavert, Pharmacia) for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or medical therapies, or for whom those treatments are inappropriate. Pegvisomant is the first of a new class of drugs called growth hormone receptor antagonists.
Q&A: Pharmacist Turned Coffee Shop Owner on the Current State of Independent Pharmacy
May 17th 2024Chris Schaffner, owner of Schaffner Pharmacy and Apothecary Coffee in Sedro Woolley, Washington, discussed the state of today’s independent pharmacy market, as well as his own pharmacy operations.